My Dad is now at 87 months, thanks to thalidomide + a steroid. Unfortunately that failed, recently, so is now onto second line treatment (Blenrep)
April 5, 2026 at 11:04 AM
My Dad is now at 87 months, thanks to thalidomide + a steroid. Unfortunately that failed, recently, so is now onto second line treatment (Blenrep)
Not sure why Reuters deleted that post but here's the news from STAT:
FDA advisers say risks of GSK blood cancer drug outweigh benefits in surprise setback
FDA advisers on Thursday voted against GSK's blood cancer drug Blenrep, finding that its risks outweighed its benefits at the selected dose
www.statnews.com
July 17, 2025 at 10:25 PM
Not sure why Reuters deleted that post but here's the news from STAT:
Confirmed this week that my body is still trying to kill me. Another two months until I start new treatment of Blenrep approximately #$US 75,000 a month. Which I thankfully won’t have to pay. Current cost of keeping me alive - somewhere over a million dollars.
July 24, 2026 at 1:40 PM
Confirmed this week that my body is still trying to kill me. Another two months until I start new treatment of Blenrep approximately #$US 75,000 a month. Which I thankfully won’t have to pay. Current cost of keeping me alive - somewhere over a million dollars.
GSK's Blenrep Gets Approval in European Union for Treating Multiple Myeloma
July 24, 2025 at 4:03 PM
GSK's Blenrep Gets Approval in European Union for Treating Multiple Myeloma
🚨 GSK’s antibody-drug conjugate Blenrep ⬇️ risk of myeloma death by 42% compared with Darzalex in their respective combinations with bortezomib and dexamethasone (planned interim analysis of the phase 3 DREAMM-7 trial)
www.fiercepharma.com/pharma/survi...
www.fiercepharma.com/pharma/survi...
ASH: With survival win against J&J's Darzalex, GSK bolsters case for return of myeloma ADC Blenrep
GSK’s antibody-drug conjugate Blenrep has mounted a sizable patient survival benefit among certain multiple myeloma patients in a head-to-head comparison against Johnson & Johnson’s industry-le | GSK’...
www.fiercepharma.com
December 9, 2024 at 10:12 PM
🚨 GSK’s antibody-drug conjugate Blenrep ⬇️ risk of myeloma death by 42% compared with Darzalex in their respective combinations with bortezomib and dexamethasone (planned interim analysis of the phase 3 DREAMM-7 trial)
www.fiercepharma.com/pharma/survi...
www.fiercepharma.com/pharma/survi...
US FDA approve GSK's blood cancer treatment reut.rs/43x8dSM
US FDA approve GSK's blood cancer treatment
The U.S. Food and Drug Administration has approved British drugmaker GSK's blood cancer drug, Blenrep, in combination with other treatments, the company said on Thursday, paving the way for a relaunch of the drug after three years.
reut.rs
October 23, 2025 at 8:10 PM
US FDA approve GSK's blood cancer treatment reut.rs/43x8dSM
GSK falls as blood cancer drug likely headed for US rejection reut.rs/3Iy5AZz
GSK falls as blood cancer drug likely headed for US rejection
GSK shares fell more than 6% on Friday to the bottom of Britain's blue-chip index after a U.S. FDA advisory panel recommended against approving its blood cancer drug Blenrep, citing earlier concerns over side effects.
reut.rs
July 18, 2025 at 8:45 AM
GSK falls as blood cancer drug likely headed for US rejection reut.rs/3Iy5AZz
FDA staff flags eye safety risks for GSK's blood cancer drug reut.rs/44QtJC7
FDA staff flags eye safety risks for GSK's blood cancer drug
The U.S. Food and Drug Administration's staff reviewers on Tuesday raised safety concerns that GSK's blood cancer drug Blenrep, when used in combination with other treatments, may cause eye damage in patients.
reut.rs
July 15, 2025 at 10:05 PM
FDA staff flags eye safety risks for GSK's blood cancer drug reut.rs/44QtJC7
FDA advisers vote against combination therapies of GSK's blood cancer drug reut.rs/40kK94g
FDA advisers vote against combination therapies of GSK's blood cancer drug
The U.S. Food and Drug Administration's panel of independent advisers voted on Thursday against approval of GSK's blood cancer drug Blenrep for use in combination with other treatments.
reut.rs
July 17, 2025 at 5:15 PM
FDA advisers vote against combination therapies of GSK's blood cancer drug reut.rs/40kK94g
The MMRF weighs in on the latest Blenrep (belantamab mafodotin) news and what it means for patients. With the FDA's decision pending, we’re closely watching next steps. Stay informed and read more 👉 themmrf.org/mmrf-blogs/t... #MultipleMyeloma #Blenrep
The State of Blenrep: What Patients Should Know - MMRF
The MMRF supports FDA approval of Blenrep (belantamab mafodotin) as a meaningful treatment option for patients with relapsed/refractory multiple myeloma. In the coming days, the FDA will decide whethe...
themmrf.org
July 22, 2025 at 1:21 PM
The MMRF weighs in on the latest Blenrep (belantamab mafodotin) news and what it means for patients. With the FDA's decision pending, we’re closely watching next steps. Stay informed and read more 👉 themmrf.org/mmrf-blogs/t... #MultipleMyeloma #Blenrep
Health Canada has approved Blenrep combinations for relapsed/refractory myeloma after at least one prior treatment. This marks a major step forward for myeloma patients in Canada. Learn more: https://mmsm.link/4m9HuCO
@myelomacanada.bsky.social
#mmsm
@myelomacanada.bsky.social
#mmsm
July 23, 2025 at 9:29 PM
Health Canada has approved Blenrep combinations for relapsed/refractory myeloma after at least one prior treatment. This marks a major step forward for myeloma patients in Canada. Learn more: https://mmsm.link/4m9HuCO
@myelomacanada.bsky.social
#mmsm
@myelomacanada.bsky.social
#mmsm
"One challenge with this drug is some eye-related side effects like blurry vision. But giving it less frequently lowers this risk. Many patients, especially those not eligible for CAR T, could benefit from Blenrep (belantamab mafodotin) given every 8 to 12 weeks."
#AskTheIMF
#AskTheIMF
August 21, 2025 at 6:32 PM
"One challenge with this drug is some eye-related side effects like blurry vision. But giving it less frequently lowers this risk. Many patients, especially those not eligible for CAR T, could benefit from Blenrep (belantamab mafodotin) given every 8 to 12 weeks."
#AskTheIMF
#AskTheIMF
The #FDA has extended its review of Blenrep (belantamab mafodotin) for relapsed/refractory #myeloma. New decision date: Oct 23, 2025. Learn what this means for myeloma patients: https://mmsm.link/46kWcST
July 23, 2025 at 8:30 PM
The #FDA has extended its review of Blenrep (belantamab mafodotin) for relapsed/refractory #myeloma. New decision date: Oct 23, 2025. Learn what this means for myeloma patients: https://mmsm.link/46kWcST
The U.S. Food and Drug Administration has approved British drugmaker GSK's blood cancer drug, Blenrep, in one combination regimen, the company said on Thursday, clearing the way for its return to the market nearly three years after it was withdrawn.
US FDA approve GSK's blood cancer treatment
The U.S. Food and Drug Administration has approved British drugmaker GSK's blood cancer drug, Blenrep, in one combination regimen, the company said on Thursday, clearing the way for its return to the market nearly three years after it was withdrawn.
reut.rs
October 23, 2025 at 10:35 PM
The U.S. Food and Drug Administration has approved British drugmaker GSK's blood cancer drug, Blenrep, in one combination regimen, the company said on Thursday, clearing the way for its return to the market nearly three years after it was withdrawn.
GSK's blood cancer drug fails to secure US FDA advisers' support reut.rs/3GOacKu
GSK's blood cancer drug fails to secure US FDA advisers' support
The U.S. Food and Drug Administration's panel of independent advisers on Thursday recommended against GSK's blood cancer drug Blenrep, citing concerns about safety of the drug.
reut.rs
July 17, 2025 at 7:05 PM
GSK's blood cancer drug fails to secure US FDA advisers' support reut.rs/3GOacKu
The UK MHRA approves Blenrep + BVd or BPd for relapsed/refractory myeloma—marking a global first. Backed by DREAMM-7 & 8. IMF CMO Dr. Mikhael calls it "crucial to extending remission and ultimately survival." Read more: https://mmsm.link/42AXQfI
April 17, 2025 at 9:51 PM
The UK MHRA approves Blenrep + BVd or BPd for relapsed/refractory myeloma—marking a global first. Backed by DREAMM-7 & 8. IMF CMO Dr. Mikhael calls it "crucial to extending remission and ultimately survival." Read more: https://mmsm.link/42AXQfI
With GSK's Blenrep back under FDA review for 2L+ MM, here's my colleague Lauren Martz's piece about testing cancer drugs in earlier treatment settings where they may succeed -- even if they might have failed in later lines: www.biocentury.com/article/6542...
Blenrep comeback makes the case for early-first cancer approach: a Perspective
There’s an unspoken rule that cancer drugs should be tested in the sickest patients first. It’s time to turn that paradigm on its head.&...
www.biocentury.com
November 25, 2024 at 11:43 AM
With GSK's Blenrep back under FDA review for 2L+ MM, here's my colleague Lauren Martz's piece about testing cancer drugs in earlier treatment settings where they may succeed -- even if they might have failed in later lines: www.biocentury.com/article/6542...
US FDA extends review of GSK's blood cancer drug reut.rs/3IHHmvO
US FDA extends review of GSK's blood cancer drug
The U.S. Food and Drug Administration has extended its review of GSK's blood cancer drug Blenrep as a combination treatment, the company said on Wednesday.
reut.rs
July 23, 2025 at 4:35 PM
US FDA extends review of GSK's blood cancer drug reut.rs/3IHHmvO
GSK shares fall after blood cancer drug likely headed for U.S. rejection reut.rs/4m5GrnA
GSK shares fall after blood cancer drug likely headed for U.S. rejection
GSK shares fell more than 6% on Friday after a U.S. FDA advisory panel recommended against approving its blood cancer drug Blenrep, citing earlier concerns over eye-related side effects.
reut.rs
July 18, 2025 at 7:50 AM
GSK shares fall after blood cancer drug likely headed for U.S. rejection reut.rs/4m5GrnA
Today, the U.S. FDA has approved Blenrep (with bortezomib + dexamethasone) for adults with relapsed/refractory multiple myeloma after 2+ prior treatments. Read now: https://mmsm.link/4qv2Cqc
#mmsm #myeloma
#mmsm #myeloma
October 23, 2025 at 11:32 PM
Today, the U.S. FDA has approved Blenrep (with bortezomib + dexamethasone) for adults with relapsed/refractory multiple myeloma after 2+ prior treatments. Read now: https://mmsm.link/4qv2Cqc
#mmsm #myeloma
#mmsm #myeloma
The revitalisation of #GSK's #Blenrep has continued with the news that the #NHS in #England can use the #BCMAtargeting #multiplemyeloma drug more widely.
Multiple myeloma drug Blenrep backed for wider NHS use
The revitalisation of GSK's Blenrep has continued with the news that the NHS in England can use the BCMA-targeting multiple myeloma drug more widely.
buff.ly
April 17, 2026 at 2:15 PM
The revitalisation of #GSK's #Blenrep has continued with the news that the #NHS in #England can use the #BCMAtargeting #multiplemyeloma drug more widely.
Blenrep is the only anti-BCMA accessible in the community setting where 70% of patients receive care.
Blenrep approved by US FDA for use in treatment of relapsed/refractory multiple myeloma | GSK
www.gsk.com
October 24, 2025 at 7:22 AM
Blenrep is the only anti-BCMA accessible in the community setting where 70% of patients receive care.